Compugen   drug  diagnostic discovery company providing  product candidates addressing  unmet therapeutic  diagnostic   pharmaceutical, biotech  diagnostic companies  milestone  royalty bearing,   revenue sharing agreements. Unlike traditional  throughput trial  error experimental based discovery, Compugen' discovery efforts consist   silico ( computer) hypothesis-driven product candidate prediction  selection    vitro   vivo experimental validation. Compugen' unique  silico prediction  selection capabilities  based   broad  continuously growing infrastructure  proprietary scientific understandings  predictive platforms, algorithms, machine learning systems   computational biology tools. Industry collaborations   entered   product candidate discovery  undertaken pursuant  "discovery  demand" type arrangements,   respect  existing product candidates,   initiated prior ,    proof  concept stage,   selected preclinical activities   undertaken  Compugen. In 2002, Compugen established  affiliate, Evogene Ltd. (TASE: EVGN.TA) -  utilize    Company'  silico predictive discovery capabilities  agricultural biotechnology.
